Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

Yaron Bar-Dayan, M. Eric Gershwin, Yaîr Levi, Howard Amital, Yehuda Shoenfeld

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease, which is invariably fatal. Circumstantial and indirect evidence suggests that autoimmune mechanisms have a role in the genesis of PBC. Antimitochondrial antibodies (AMA) are highly sensitive and specific markers that can predict the development of the disease in a healthy individual. Long-term administration of ursodeoxycholic acid (UDCA), a naturally occurring bile acid, safely slows the progression of PBC, delays the need for liver transplantation, and postpones death. An effort should be made to identify the patients with PBC in the asymptomatic stage by the presence of AMA and to conduct a clinical trial in order to assess the benefit of long-term administration of UDCA on the prevention of the overt disease in these individuals.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalImmunologic Research
Volume18
Issue number2
StatePublished - 1998

    Fingerprint

Keywords

  • Antimitochondrial antibodies
  • Prediction prevention
  • Primary biliary cirrhosis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Immunology

Cite this

Bar-Dayan, Y., Gershwin, M. E., Levi, Y., Amital, H., & Shoenfeld, Y. (1998). Primary biliary cirrhosis. Is (and how much of) the pathology preventible? Immunologic Research, 18(2), 117-123.